UNSPSC 51162317: Acetaminophen/dexbrompheniramine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE515. This VA Drug Class (RE515) classifies this compound as belonging to the group DECONGESTANT/ANTITUSSIVE/ANALGESIC.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51162317 Acetaminophen/dexbrompheniramine/pseudoephedrine is a Commodity code capturing branded and generic combinations of over-the-counter cold and allergy medications that state and local governments procure for public health programs, emergency response systems, and healthcare facilities. Recent solicitations show state and local agencies buying these products as components of broader pharmaceutical procurement contracts, particularly through cooperative purchasing vehicles that aggregate demand across multiple jurisdictions. The work involves supplying finished pharmaceutical products meeting FDA manufacturing standards, cGMP certification, and Drug Supply Chain Security Act compliance to authorized wholesalers and direct-delivery health facilities.

Issuing bodies include state departments of administration administering cooperative purchasing alliances and county health departments. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a proposal deadline of March 26, 2026, seeking manufacturers to supply products through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC with contract effectiveness July 1, 2026. Seminole County, Florida issued an IFB (No. IFB60459723LAS) posted June 30, 2026 for naloxone and drug deactivation systems with a July 26, 2023 response deadline, procuring 1,900 units of naloxone annually for quarterly delivery to the county health building. Geographic activity centers on the upper Midwest and Florida, with MMCAP's cooperative framework extending to participating states including Oregon. Neither solicitation applied explicit set-aside designations for disadvantaged enterprises.